Cybin Inc. (NYSE:CYBN - Free Report) - Research analysts at HC Wainwright raised their Q3 2025 earnings estimates for shares of Cybin in a research report issued on Monday, January 27th. HC Wainwright analyst P. Trucchio now anticipates that the company will post earnings of ($0.51) per share for the quarter, up from their previous forecast of ($0.53). HC Wainwright has a "Buy" rating and a $190.00 price objective on the stock. The consensus estimate for Cybin's current full-year earnings is ($4.83) per share. HC Wainwright also issued estimates for Cybin's Q4 2025 earnings at ($0.52) EPS, FY2025 earnings at ($3.54) EPS, Q1 2026 earnings at ($0.56) EPS, Q2 2026 earnings at ($0.61) EPS, Q3 2026 earnings at ($0.68) EPS, Q4 2026 earnings at ($0.77) EPS, FY2026 earnings at ($2.62) EPS, FY2027 earnings at ($0.86) EPS and FY2028 earnings at $3.84 EPS.
Separately, Canaccord Genuity Group cut their target price on shares of Cybin from $96.00 to $86.00 and set a "buy" rating on the stock in a research note on Thursday, November 14th.
Check Out Our Latest Stock Analysis on CYBN
Cybin Trading Down 0.7 %
NYSE:CYBN traded down $0.07 during trading hours on Thursday, hitting $9.84. 269,844 shares of the stock traded hands, compared to its average volume of 199,769. The business's 50 day simple moving average is $9.76. Cybin has a fifty-two week low of $6.50 and a fifty-two week high of $19.85. The firm has a market capitalization of $198.28 million, a price-to-earnings ratio of -1.48 and a beta of 0.46.
Hedge Funds Weigh In On Cybin
Hedge funds have recently modified their holdings of the stock. Global Retirement Partners LLC bought a new stake in Cybin during the fourth quarter worth approximately $46,000. Cowa LLC acquired a new position in shares of Cybin during the fourth quarter worth approximately $115,000. Finally, Sanctuary Advisors LLC acquired a new position in shares of Cybin during the second quarter worth approximately $36,000. 17.94% of the stock is owned by institutional investors and hedge funds.
About Cybin
(
Get Free Report)
Cybin Inc, a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds.
Further Reading
Before you consider Cybin, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cybin wasn't on the list.
While Cybin currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
